3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Melanoma
3
Uveal Melanoma
1
Recurrence
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Fallopian Tube Neoplasms
1
Advanced Cancer
1
Interventions
Nivolumab
6
Ipilimumab
4
6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline
2
tilsotolimod
1
relatlimab
1
mirdametinib
1
linrodostat
1
gedatolisib
1
figitumumab
1
Valganciclovir
1
Tablets
1
Surveys and Questionnaires
1
Sunitinib
1
Paclitaxel
1
LY2584702
1
Irinotecan
1
EC145
1
Dasatinib
1
Chlorogenic Acid
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Advanced Cancer
×
relatlimab
×
Clear all
NCT02750514
2021-03-22
FRACTION-Lung
Bristol-Myers Squibb
Phase 2
Terminated
295 enrolled
21 charts